Antiepileptic agents: Newer generation

Indian Journal of Pharmacology

Volumn 28, Issue 1, 1996, Pages 1-10

  Sharma, A K ^a   Khosla, R ^a   Mehta, V L ^a   Kela, A K ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

antiepileptics; GABA; K+ channel; NMDA

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALLOPURINOL; ANTICONVULSIVE AGENT; APRIKALIM; BENZODIAZEPINE; CROMAKALIM; DIAZEPAM; DIZOCILPINE; FELBAMATE; FLUNARIZINE; FLUOXETINE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXCARBAZEPINE; PHENYTOIN; POTASSIUM CHANNEL STIMULATING AGENT; PRODRUG; PROGABIDE; STIRIPENTOL; TOPIRAMATE; UNINDEXED DRUG; VIGABATRIN;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; EPILEPSY; EPILEPTIC STATE; FOCAL EPILEPSY; GABAERGIC SYSTEM; GENERALIZED EPILEPSY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0029971431     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Schechter PJ, Tranier Y, Jung MJ, et al. Audiogenic seizure protection by elevated braun GABA concentration in mice: effects of gamma-acetylenic GABAand gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 1977;45:319-28.
2. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989;27:101-107.
3. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;6:52-9.
4. Livingston JH, Beaumont D, Arzimanoglou A, et al. Vigabatrin in the treatment of epilepsy in children. Br J Clin Pharmacol 1989;27:109-12.
5. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebocontrolled study. Epilepsia 1989;30:430-37.
6. Frisk-Holmberg M, Kerth P, Meyer Ph. Effect of food on the absorption of vigabatrin. Br J Clin Pharmacol 1989; 27:23-5.
7. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991;41:889-926.
8. Ring HA, Trimble MR, Costa DC, et al. Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol. Neuro- surgery and Psychiatry 1992;55:758-61.
9. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989;27:27-33.
10. Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneim Forsch Drug Res 1984; 34:199-204.
11. Rascol O, Squalli A, Montastruc JL, et al. A pilot study of stiripentol, a new anticonvulsant drug, in complex partial seizures uncontrolled by carbamazepine. Clin Neuropharmacol 1989;12:119-23.
12. Martinez-Lange M, Loiseau P, Levy RH, et al. Clinical antiepileptic efficacy of stiripentol in resistant partial epilepsies. Epilepsia 1984;25:673.
13. Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 1993;34:305-11.
14. Loiseau P, Duche B. Stiripentol, In: Levy R, Mattson R, Meldrum B, et al., eds. Potential antiepileptic drugs. 3rd ed. New York: Raven Press Ltd. 1989:955-69.
15. Loiseau P, Tor J. Stiripentol in absence seizures. Epilepsia 1987;28:579.
16. Martinez-Lange M, Levy RH, Gjonzafez I, et al. Stiripentol in therapy-resistive and severe epileptic patients: a long-term open trial in bitherapy. In: Wolf P, Dam M, Janz D, et al., eds. Advances in epileptology. Vol.16. New York: Raven Press Ltd. 1987:541-6.
17. Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos 1986;14:654-62.
18. Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: non-linearity and interactions. Clin Pharmacol Ther 1984;36:661-9.
19. Worms P, Depoortere H, Durand A, et al. r-Aminobutyric acid (GABA) receptor stimulation. I neuropharmacological profile of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectrum. J Pharmacol Exp Ther 1982;220:660-71.
20. Morselli PL, Bartholini G, Uoyd KG. Progabide. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant drugs. London: John Libbey 1986:237-53.
21. Dam M, Gram L, Philbert A, et al. Progabide: a controlled trial in partial epilepsy. Epilepsia 1983;24:127-35.
22. Schmidt D, Utech K. Progabide for refractory partial epi -lepsy: A controlled add on trial. Neurol 1986;36:217-21.
23. Leppik IE, Dreifuss FE, Porter RJ, et al. A controlled study of progabide in partial seizures: methodology and results. Neurol 1987;37:963-8.
24. Rogawski MA, Porter RJ. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacological Reviews 1990;42:223-86.
25. Miller AA, Wheatley PL, Sawyer DA, et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986;27:483-9.
26. Wheatley PL, Miller AA. Effects of lamotrigine on electrically induced after discharge duration in anaesthetised rat, dog and marmoset. Epilepsia 1989;30:34-40.
27. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-76.
28. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-97.
29. Oller L, Russi A, Oiler Daurella L Lamotrigine in Lennox-Gastaut syndrome. Abstract. Epilepsia 1991;32:58.
30. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991;32:9-12.
31. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-1400.
32. Betts T, Goodwin G, Withers RM, et al. Human safety of Lamotrigine. Epilepsia 1991;32:17-21.
33. Faught ER, Leroy RF, Messenheimer JA, et al. Clinical experience with lamotrigine ("Lamictal") monotherapy for partial seizures in adult outpatients. Abstract Epilepsia 1992;33:82.
34. Warner T, Patsalos PN, Prevett M, et al. Lamotrigine- induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992;11:147-50.
35. . Leppik IE, Boucher BA, Wilder BJ, et al. Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurol 1990;40:456-60.
36. Varia SA, Stella VS, Phenytoin prodrug VI: in vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J Pharm Sci 1984;73:1087-90.
37. Varia SA, Stella VS. Phenytoin prodrug: in vivo evaluation of some water soluble phenytoin prodrugs in dogs. J Pharm Sci 1984;73:1080-87.
38. Leppik IE, Boucher R, Wilder BJ, et al. Phenytoin prodrug preclinical and clinical studies. Epitepsia 1989;30:S22-6.
39. Baltzer V, Schmutz M. Experimental anticonvulsive properties of GP 47 680 and GP 47 779, its main human metabolite: compound related to carbamazepine. Advances in Eileptology 1977;295:299.
40. Patsalos PN, Elyas AA, Zakrewska JM. Protein binding of oxcarbazepine and its primary metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 1990;39:413-5.
41. Dickinson RG, Hooper WD, Dunstan PR, et al. First dose and steady state pharmaookinetics of oxcarbazepine and Hs 10-hydroxy metabolite. Eur J Clin Pharmacol 1989;37:69-74.
42. Kristensen O, Klirtgaard NA, Jonsson B, et al. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurologica Scandinavica 1983;68: 145-50.
43. Kumps A, Wurth C. Oxcarbazepine disposition: preliminary observations in patients. Biopharmaceutics and Drug Disposition 1990;11:365-70.
44. Dam M, Ekberg R, Loyning Y, et al. A double blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3:70-7.
45. Reinikainen KJ, Keranen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double blind study. Epilepsy Res 1987;1:284-9.
46. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out patietns on oxcarbazepine treatment. Acta Neurologica Scandinavica 1993;87:224-7.
47. Sillanpaa M. Carbamazepine. In: Wyllie, ed. The treatment of epilepsy: principles and practice. Philadelphia: Lea and Febiger 1993:867-86.
48. Keranen T, Jolkkonen J, Jensen PK, et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurologica Scandinavica 1992a;86:120-23.
49. Keranen T, Jolkkonen J, Klosterskov-Jensen P, et al. Oxcarbazepine does not interact with cimetidine in healthy lunteers. Acta Neurological Scandinavica 1992b;85:239-42.
50. Mogensen PH, Jorrgensen L, Bjoas J, et al. Effects of dextropropoxyphene on the steady state kinetics of oxcarbazepine and its metabolites. Acta Neurological Scandinavica 1992;85:14-7.
51. Kramer G, Tettendorn B, Klosterskov Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992;33:1145-8.
52. Klosterskov Jensen P, Sanno V, Haring P, et al: Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-52.
53. Battino D, Croci D, Granata T, et al. Changes unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine. Therapeutic Drug 1992;14:376-9.
54. Houtkooper MA, Lammertsma A, Meye JWA, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
55. Todd PA, Benfield P. Flunarizine: a reappraisal of its pharmacological properties and therapeutic use in neurological disorders. Drugs 1989;38:481-99.
56. Strarreveld E, de Beukelaar F, Wilson AF, et al. Double blind cross-over placebo controlled study of flunarizine in patients with therapy resistant epilepsy. Can J Neural Sci 1989;16:187-90.
57. Overwig J, Binnie CD, Meijer JWA, et al. Double blind placebo controlled trial of flunarizine as add-on therapy in epilepsy. Epilepsia 1984;25:217-22.
58. Moglia A, Bergamasco B, Di Perri R, et al. Flunarizine as add-on therapy in epilepsy crossover study versus placebo. Funct Neurol 1986;1:547-50.
59. Kataoka K, Kanamori N, Oishi M, et al. Determination of flunarizine in serum by high performance liquid chromatogrphy and its clinical application. Yakugaku Zasshi 1988;108:226-31.
60. Kapetanovic FM, Torchin CD, Kupferberg HJ, et al. Pharmacokinetic profile of flunarizine after single and multiple dosing in epileptic patients receiving comedication. Epilepsia 1988;29:770-74.
61. Maryanoff BE, Nortey SO, Gardockin JF, et al. Anticonvulsant O-alkylsurfamates. 2,3:4,5-Bis-O-(1-methylidene)-B-D-fructopyranose sulfamate and related compounds. J Med Chem 1987;30:880-87.
62. Nakamura J, Tamura S, Kandr T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994;254:83-9.
63. Dhank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
64. . Floren KL, Graves NM, Leppik IE, et al. Pharmacokmetics of topiramate in patients with partial epilepsy receiving phenytoin or valproate. Epilepsia 1989;30:646.
65. Wilensky AJ, Ojemann LM, Chmelir T, et al. Topiramate pharmacokinetics in epileptic patients receiving carbamazepine. Epilepsia 1989;30:645.
66. Amrein R, Hetzel W. Pharmacology of drugs frequency used in ICUs: midazolam and flumazenil. Intensive Care Med 1991;17:51-10.
67. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992;20:483-8.
68. Riveria R, Segnini M, Baltodano A, et al. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993;21:991-4.
69. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983;16:435-95.
70. Kanto JH. Midazolam: the first water-soluble benzodiazepine. Pharmacotherapy 1985;5:138-55.
71. Fee JPH, Collier PD, Howard PH, et al. Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 1987;41:80-4.
72. Bleck TP. Advances in the management of refractory status epilepticus. Crit Care Med 1993;21:955-7.
73. McNamera JO, Russell RD, Rigsbeel, et al. Anticonvulsant and antiepueptogenic actions of MK-801 in the kindling and electroshock models. Neuropharmacol 1988;27:563-8.
74. Pedder SCJ, Wilcox R, Tuchek JM, et al. The relationship between anticonvulsant activity and receptor affinity of N-methyl-D-asparate antagonists in epileptic fowl. Neuropharmacol 1989;28:753-6.
75. Czuczwar SJ, Meldrum BS. Protection against chemically induced seizures by 2-amino-7-phosphonoheptanoic acid. Eur J Pharmacol 1982;83:335-8.
76. De Sarro G, Meldrum BS, Reavill G. Anticonvulsant action of 2- amino-7-phosphonoheptanoic acid in the substantia nigra. Eur J Pharmacol 1984;106:175-9.
77. Coutinho Netto J, Abdul Ghani AS, Collins JF, et al. Is glutamate a triger factor in epileptic hyperactivity? Epilepsia 1981;22:289-96.
78. Morris RGM, Anderson E, Lynch GS, et al. Selective impairment of learning and blockade of long term potentiation by an N-methyl-D-aspartate receptor antagonist AP5. Nature 1986;319:774-6.
79. Morris RGM, Davis S, Butcher SP. The role of NMDA receptors in learning and memory. In: Watkins JC, Colngridge GJ, eds. The NMDA receptor. Oxford: IRL Press 1989:137-51.
80. Tricklebank MD, Singh L, Oles RJ, et al. The behavioural effects of MK-801: a comparison with antagonists acting non- competitively and competitively at NMDA receptor. Eur J Pharmacol 1989;167:127-35.
81. Byrd LD, Standish LJ, Howell LL. Behavioural effects of phencydidine and ketamine alone and in combination with other drugs. Eur J Pharmacol 1987;144:331-41.
82. Thurkanf A, Decosta B, Yamaguchi S, et al. Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogues. J Med Chem 1990;33:1452-8.
83. + channel openers prevent epilepsy induced by the bee venom peptide MCD. Eur J Pharmacol 1989;159:329-30.
84. + channel openers decrease seizures in genetically epileptic rats. Eur J Pharmacol 1989;167:181-3.
85. Cherubini E, Ben Ari Y, Gho M, et al. Long term potentiation of synaptic transmission in the hippocampus induced by a been venom peptide. Nature 1985;328:70-73.
86. Van QS, Jobe PC, Dailey JW. Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy prone rats. Eur J Pharmacol 1994;252:105-12.
87. Leppik IE, Graves NM. Potential antiepileptic drugs: felbamate. In: Levy et al. ed. Antiepileptic drugs. 3rd ed. New York: Raven Press 1989:983-90.
88. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41:1785-9.
89. Sachdeo RC, Murphy JV, Kamin M. Felbamate in juvenile myoclonus epilepsy. Abstract. Epilepsia 1992;33:118.
90. Devinsky O, Kothari M, Rubin R, et al. Felbamate for absence seizures. Abstract. Epilepsia 1992;33:84.
91. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial onset seizures: an active control trial. Neurology 1993;43:688-92.
92. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991;32:130-32.
93. . Feurst RH, Graves NM, Leppik IE, et al. Felbamate increases phenytoin but decreases earbamazepine concentrations. Epilepsia 1988;29:488-91.
94. Bartoszyk GD, Meyerson N, Reimann W, et al. New anticonvulsant drugs: gabapentin. In: Meldrun and Porter, eds. Vol.4. Current problems in epilepsy. London: John Libbey 1986:147-63.
95. Loscher W, Honack D, Taylor CP. Gabapentin increases aminooxyacetic acid-induced GABA accumulation in several regions of rat brain. Neuroscience Letters 1991;128:150-54.
96. 3H]-gabapentin binding sites in rodent brain. Abstract. Br J Clin Pharmacol 1991;104:72.
97. Browne TR. Long-term efficacy and toxicity of gabapentin. Abstract Neurology 1993;43:307.
98. Abou-Khalil B, Shellenberger MK, Anhut H. Two open-label multicenter studies of gabapentin in patients with refractory epilepsy. Abstract. Epilepsia 1992;33:77.
99. Bauer G, Bechinger D, Castell M, et al. Gabapentin in the treatment of drug-resistant epileptic patients. Advances in Epileptology 1989;17:219-21.
100. Sivenius J, Kalviainen R, Ylinen A, et al. Double blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991;32:539-42.
101. Eldon MA, Underwood BA, Randinitis EJ, et al. Lack of effect of gabapentin on the pharmacokinetics of a norethindrone acetate/ethinyl estradiol containing oral contraceptive. Abstract. Neurology 1993;43:307.
102. Graves NM, Holmes GB, Leppik E, et al. Pharmacokinetics of gabapentin in patients treated with phenytoin. Abstract. Pharmacotherapy 1989;9:196.
103. Hooper WD, Kavanagh MC, Herkes GK, et al. Lack of pharmacokinetic interaction between phenobarbitone and gabapentin. Br J Clin Pharmacol 1991;31:171-4.
104. Zagnoni PG, Bianchi A, Zolo P, et al. Allopurinol as add on therapy in refractory epilepsy: a double blind placebo controlled randomised study. Epilepsia 1994;35:107-12.
105. Tada K, Morooka K, Arimoto K, et al. Clinical effects of allopurinol on intractable epilepsy. Epilepsia 1991;32:279-83.